What are your top takeaways from ACR 2022?

• Risk stratification for cardiovascular risk with JAKi (Ytterberg et al., PMID 35081280 and more specifically subgroup analysis by Charles-Schoeman et al., PMID 36137735): heightened risk in patients with history of atherosclerotic CV disease-ASCVD (defined as CAD, stroke, PAD)-NNH only 16 over 5 ye...

• 1678. A Genome-Wide Association Analysis of 2,622,830 Individuals Reveals New Pathogenic Pathways in Gout by Dr. Tony Merriman, which found many different new genes that are pathogenic in gout and could potentially lead to new treatments.
• 12-month findings of the MIRROR RCT trial, which show that m...

• CAR-T cell therapy for lupus nephritis
• TLR7 monogenic lupus
• CD38+ “rogue” T cells in macrophage activation syndrome

Thanks for this thread (from someone who could not attend ACR this year). I hope others chime in.